Arcutis Biotherapeutics (NASDAQ:ARQT) Price Target Raised to $19.00 at Jefferies Financial Group

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) had its target price increased by investment analysts at Jefferies Financial Group from $16.00 to $19.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Jefferies Financial Group's price objective indicates a potential upside of 23.91% from the stock's previous close.

Several other equities research analysts have also recently weighed in on the company. Mizuho increased their price objective on Arcutis Biotherapeutics from $20.00 to $21.00 and gave the stock an "outperform" rating in a report on Wednesday, February 26th. Guggenheim restated a "buy" rating on shares of Arcutis Biotherapeutics in a report on Monday, February 24th. The Goldman Sachs Group increased their target price on Arcutis Biotherapeutics from $13.00 to $15.00 and gave the stock a "neutral" rating in a research report on Thursday, February 27th. Needham & Company LLC restated a "buy" rating and set a $20.00 price target on shares of Arcutis Biotherapeutics in a research report on Wednesday, February 26th. Finally, HC Wainwright reiterated a "buy" rating and issued a $19.00 price objective on shares of Arcutis Biotherapeutics in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Arcutis Biotherapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $18.80.

Arcutis Biotherapeutics Trading Up 6.6 %

NASDAQ:ARQT traded up $0.95 during trading hours on Tuesday, reaching $15.33. The company's stock had a trading volume of 1,602,468 shares, compared to its average volume of 2,207,693. The firm has a 50-day simple moving average of $13.45 and a 200-day simple moving average of $11.72. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.38 and a current ratio of 2.46. Arcutis Biotherapeutics has a 1 year low of $6.99 and a 1 year high of $16.20. The firm has a market capitalization of $1.82 billion, a price-to-earnings ratio of -8.48 and a beta of 1.48.

Remove Ads

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) earnings per share for the quarter, beating analysts' consensus estimates of ($0.28) by $0.19. The firm had revenue of $71.36 million during the quarter, compared to analyst estimates of $60.52 million. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%. Research analysts expect that Arcutis Biotherapeutics will post -1.33 EPS for the current fiscal year.

Insider Buying and Selling at Arcutis Biotherapeutics

In related news, insider Masaru Matsuda sold 8,338 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $12.70, for a total value of $105,892.60. Following the transaction, the insider now owns 178,692 shares of the company's stock, valued at approximately $2,269,388.40. This trade represents a 4.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Todd Franklin Watanabe sold 15,000 shares of the company's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $15.17, for a total transaction of $227,550.00. Following the sale, the insider now directly owns 823,430 shares of the company's stock, valued at approximately $12,491,433.10. This represents a 1.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 57,848 shares of company stock worth $797,648. Insiders own 9.50% of the company's stock.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ARQT. GF Fund Management CO. LTD. bought a new position in shares of Arcutis Biotherapeutics during the 4th quarter valued at approximately $34,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Arcutis Biotherapeutics by 1.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 280,100 shares of the company's stock worth $3,902,000 after buying an additional 3,409 shares during the period. Voloridge Investment Management LLC increased its stake in Arcutis Biotherapeutics by 126.5% in the 4th quarter. Voloridge Investment Management LLC now owns 290,938 shares of the company's stock worth $4,053,000 after buying an additional 162,495 shares in the last quarter. Squarepoint Ops LLC raised its holdings in Arcutis Biotherapeutics by 67.2% during the fourth quarter. Squarepoint Ops LLC now owns 121,392 shares of the company's stock valued at $1,691,000 after acquiring an additional 48,769 shares during the period. Finally, Suvretta Capital Management LLC raised its holdings in Arcutis Biotherapeutics by 6.3% during the fourth quarter. Suvretta Capital Management LLC now owns 11,399,138 shares of the company's stock valued at $158,790,000 after acquiring an additional 677,627 shares during the period.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.